+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
138.8600
3.5000
Low
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
As an important resource for drug discovery, natural products show broad application prospects in fields such as antibacterial, anti-tumor, and antiparasitic areas due to their structural diversity and rich biological activity. Albaspidin AA (CAS No.: 3570-40-9) is a natural product derived from specific plants. In recent years, it has attracted widespread attention due to its significant inhibition of the vegetative morphology of Legionella pneumophila and its in vitro killing activity against the L4 larval stage of nematode. In addition, the potential regulatory role of White-Cotton Horse AA on targets related to chronic myeloproliferative disease (CMPD) suggests its application value in the treatment of hematologic diseases.
This paper aims to systematically review the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of Bai Mian marxin AA, druggability evaluation, and pharmacokinetic characteristics, and explore its future clinical application prospects, providing scientific support for further drug development and clinical translation.
The molecular formula of White-Cotton Horse AA is C_22H_28O_6, with a molecular weight of 388.40 Da. Its structure includes multiple oxygen heterocycles and phenolic hydroxyl groups, has high polarity, and presents as a large number of hydrogen bond acceptors (8), which balances water solubility and membrane permeability. A LogP value of 3.5 indicates moderate lipid solubility, which facilitates cell membrane penetration without excessive hydrophobicity that reduces bioavailability. The topological pole surface area (TPSA) is 138.86 Ų, indicating strong polarity that may limit its ability to cross the blood-brain barrier, which is consistent with its low blood-brain barrier permeability.
The chemical framework of White-Stocked Horse AA is stable, with multiple phenolic hydroxyl groups and ether bonds. These structural units not only confer antioxidant activity but may also participate in binding to biological targets. The complexity of its structure makes multi-target action possible, while also laying the foundation for synthetic modification and structural optimization.
Equinoxin AA was originally isolated from plants of the genus Eugenera, which is widely distributed in temperate and subtropical regions and has traditionally been used in traditional medicine to treat infectious diseases and parasitic diseases. This compound is usually found in plant roots, stems, and leaves, with its content varying with growth stages and environmental conditions.
Common methods for extracting Rycosa Bricantilis AA include organic solvent extraction, ultrasound-assisted extraction, and liquid chromatography separation. Ethanol or methanol is generally used as extraction solvents to ensure full dissolution of polar and non-polar components. The extract is concentrated, separated, and purified by silica gel column chromatography, then purified by high-performance liquid chromatography (HPLC) for purity detection and quantitative analysis.
In recent years, green extraction technologies such as supercritical CO_2 extraction and microwave-assisted extraction have shown advantages in improving the extraction efficiency and purity of Rycosin AA, and help reduce the use of organic solvents, aligning with the environmental trend of modern natural product extraction.
Albekima Equinoxin AA showed significant inhibitory effects on the trophic morphology of Lareicella, with a minimum inhibitory concentration (MIC) ranging from 0.168 to 220 micromoles, demonstrating strong antibacterial activity. As an important opportunistic pathogen, Lares bacteria can cause severe respiratory infections, especially in immunocompromised populations. The inhibition of its nutrient body by Alukino AA helps control the spread of infection and disease progression.
In addition, the antibacterial activity of Aluka Cotton-Equinoquin AA against other Gram-negative and Gram-positive bacteria has not been systematically studied. Future research on its antimicrobial spectrum needs further expansion to assess its potential as a broad-spectrum antimicrobial.
In vitro experiments showed that White-Cotton-Horse AA had a killing effect on nematode L4-stage larvae, suggesting its application value in the field of antiparasitic disease. Nematode infection is a major global public health issue, especially in tropical and subtropical regions. White-Cotton Horse AA disrupts the physiological functions of nematodes and is expected to become a candidate molecule for new anti-nematode drugs.
However, the differences in activity of White-Cottonmarin AA against different nematode species and developmental stages still need further clarification. In addition, optimizing its in vivo efficacy, toxicity, and administration regimen is also a key focus of future research.
Chronic myeloproliferative diseases are a class of hematologic disorders characterized by abnormal proliferation of hematopoietic cells in the bone marrow. Alukinomarin AA has been found to act on multiple molecular targets including MCL1, ALOX5, TOP2A, BCL2L1, and IMPDH2, which play key roles in apoptosis regulation, inflammatory responses, and DNA topoisomerase activity.
By regulating these targets, Eutrophenin AA is expected to inhibit abnormally proliferating bone marrow cells, induce their apoptosis, and thereby improve disease progression. Currently, most related research consists of in vitro cell experiments and molecular docking analyses, lacking systematic in vivo validation and clinical data.
The multi-target mechanism of alkalimasu AA provides a theoretical basis for its complex pharmacological effects. The main targets include:
MCL1 (Myeloid cell leukemia 1): As an anti-apoptotic protein, MCL1 plays an important role in the survival of various tumor cells. Alukinein AA may promote apoptosis by inhibiting MCL1 expression or function, especially in cells with myelodysplastic abnormalities.
ALOX5 (5-lipoxygenase): Involved in the synthesis of inflammatory mediators and regulates immune responses. Inhibition of ALOX5 by Alukinoma AA may reduce inflammatory responses and improve the pathological environment of chronic bone marrow diseases.
TOP2A (DNA Topoisomerase IIα): A key DNA helicase involved in DNA replication and transcription. Mummyoxin AA may inhibit TOP2A activity, block cell cycle progression, and suppress abnormal cell proliferation.
BCL2L1 (Bcl-xL): a member of the anti-apoptotic protein family, regulates cell survival. The action of White-Felix Horse AA may impair BCL2L1 function and promote apoptosis.
IMPDH2 (inosine dehydrogenase 2): a key enzyme for nucleotide synthesis, affecting cell proliferation. White-Lim Horse Hormone AA may inhibit IMPDH2, restrict nucleotide supply, and suppress cell proliferation.
Molecular docking and cell experiments have shown that Eumatronin AA can form stable binding to these targets, affecting its functional activity. Additionally, its antibacterial and anti-nematode effects may involve multiple mechanisms such as damaging cell membrane integrity, interfering with energy metabolism, and inducing oxidative stress.
The druggability parameters of Baimianma Su AA indicate that it has certain potential for drug development:
The molecular weight is 388.4 Da, which fits the ideal range of Lipinski's rules and is conducive to oral absorption.
LogP 3.5, moderate lipid solubility aids membrane penetration, but excessive levels may affect water solubility and bioavailability.
TPSA 138.86 Ų, with higher polarity, may limit oral absorption and blood-brain barrier penetration, consistent with its low blood-brain barrier permeability.
There are 8 hydrogen bond receptors, and a higher number of hydrogen bond receptors helps bind to the target but may affect membrane permeability.
Currently, there is no clear data on hepatotoxicity, cardiotoxicity (including hERG channel inhibition), and genotoxicity (Ames test) of White-Cotton-Horse AA, requiring systematic toxicological evaluation. In terms of pharmacokinetics, there is a lack of in vivo data on absorption, distribution, metabolism, and excretion (ADME). Future research should focus on bioavailability, half-life, and metabolic pathways.
Based on the multiple activities of White-Cotton Horse AA on antibacterial, antinematode, and chronic myeloproliferative disease targets, its clinical application prospects are promising. Specifically, it includes:
Anti-infective therapy: For pneumonia and other infections caused by Lareiella, Meitomarin AA may become a new type of antimicrobial drug, especially significant in the context of the increasing number of multidrug-resistant strains.
Development of antiparasitic drugs: Further validation and optimization of the anti-nematode activity of Alekinomarin AA is expected to expand its application as an antiparasitic drug to meet global demand for parasitic disease prevention and control.
Hematologic disease treatment: By regulating key apoptotic and proliferative targets, Lengmanzin AA may offer a new therapeutic strategy for chronic myeloproliferative diseases, especially suitable for combining with existing targeted drugs to improve efficacy and resistance.
Future research should focus on in vivo efficacy evaluation, toxicological safety testing, and pharmacokinetic studies of Bai Mianmasu AA, while also using structural optimization and drug delivery technologies to enhance its bioavailability and targeting. Additionally, based on its multi-target characteristics, systematic network pharmacology and multi-omics studies help to fully reveal its mechanisms of action and potential indications.
As a natural product with multiple biological activities, Albeimonasu AA demonstrates significant potential for antibacterial, anti-nematode, and regulatory targets related to chronic myeloproliferative diseases. Its unique chemical structure and physicochemical properties provide the basis for its multi-target action, but systematic in vivo efficacy and safety data are still lacking. In the future, through in-depth pharmacological mechanism research, druggability optimization, and preclinical evaluation, Baimianma Su AA is expected to become an important candidate for novel anti-infective and antitumor drugs, providing new ideas and methods for the treatment of related diseases.
In summary, research on White-Cotton Horse Acid AA not only enriches the theoretical framework of natural product pharmacology but also provides valuable practical experience for natural product drug development, holding significant scientific value and application prospects.
Shenshuai
Wenjing
Hedandan
